Company Profile

Melinta Therapeutics Inc (AKA: Rib-X Pharmaceuticals)
Profile last edited on: 7/17/2023      CAGE: 47X55      UEI: NQLPMTG688S1

Business Identifier: Antibiotics designed to overcome drug-resistant, life-threatening infections
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

300 George Street Suite 301
New Haven, CT 06511
   (312) 767-0291
Location: Multiple
Congr. District: 03
County: New Haven

Public Profile

Formerly known as Rib-X Pharmaceuticals, in October 2013 the firm changed its name to Melinta Therapeutics. In the Summer 2017, publicly traded firm Cempra Inc. - anti-infectives - and closely held Melinta Therapeutics Inc.mergied to create an anti-infectives company retaining the Melinta name and now trading on the Nasdaq. With facilites in New Haven, CT and Lincolnhsire. IL., the firm is developing broad spectrum antibiotics with superior coverage, safety and convenience to deliver new standards of care for patients with serious infections. The Company's Nobel Prize winning, innovative platform enables a unique understanding of how antibiotics combat infection and has generated an industry leading pipeline spanning all phases of research and clinical development. A small molecule drug discovery and development company, Melinta Therapeutics is dedicated to the discovery, development and commercialization of groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI) and uncomplicated gonorrhea. A key initiative at Melinta is to develop, through the application of Nobel Prize-winning science, a new class of antibiotics designed to overcome the drug-resistant ESKAPE pathogens known to cause serious hospital infections. The firm applied in November 2011 for IPO but withdrew. Expected to be consummated later in 2017, in August 201 ist was announced that Cempra (NASDAQ:CMEPT) wil merge with privately held Melinta. The name wil be retained and wil trade on NASDAQ

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2005 1 NIH $230,220
Project Title: Computational Suite for RNA-Targeted Drug Design
2005 2 NIH $885,176
Project Title: Novel antibacterials targeting the 50S ribosomal subunit

Key People / Management

  Mark Leuchtenberger -- President and Chief Executive Officer

  Albert Collinson -- Chief Business Officer

  Robert A Conerly -- Vice President of Finance and Chief Financial Officer

  Erin M Duffy -- Chief Scientific Officer

  Scott Hopkins -- Chief Clinical Officer

  Graham Johnson -- Chief Research Officer

  William Jorgenson -- Founder

  Jarrod Longcor -- Sr. Director Business Development

  Peter Moore -- Founder

  Harry Noller -- Founder

  Anthony Sabatelli -- Assistant Vice President, Chief Patent Counse

  Thomas A Steitz -- Co-Founder

  Joyce A Sutcliffe -- Chief Research Scientist